Originally developed in Germany and used by world-class athletes, the Regenokine® Program uses autologous conditioned serum (ACS) and other healing factors from your own blood to treat osteoarthritis, sciatica, and other painful conditions.
Dr Buchheit is one of only a handful of physicians in the United States certified to offer the Regenokine® Program.
The core of the Regenokine Program, autologous conditioned serum, is derived entirely from your own blood
Rebalances the cytokines and proteins that drive arthritis and other chronic conditions
Used by professional athletes worldwide
Research shows that many patients experience relief for 2+ years
The Regenokine® Program is a regenerative therapy developed in Düsseldorf, Germany by Dr. Peter Wehling and his scientific team. The program utilizes autologous conditioned serum (ACS), a concentrated product derived from your own blood.
Dr. Buchheit has conducted extensive research with Dr. Wehling and Duke’s Center for Translational Pain Medicine, demonstrating in the lab that the benefits of ACS come from a unique combination of growth factors, inflammation-resolving proteins, and exosomes.
This non-surgical treatment program is designed to address painful conditions like osteoarthritis, tendinopathies, ligament injuries, spinal disorders, and sciatica. The Regenokine® Program has been used over 10,000 times by athletes and patients across Europe and the United States. Patients usually experience minimal downtime, less pain, and a quick return to activities and sports.
Chronic inflammation releases enzymes that damage cartilage and nerves, leading to pain.
The Regenokine® Program and its ACS help to reduce pain with multiple growth factors and inflammation-resolving cytokines such as IL-1Ra (also called IRAP). Research by Dr. Buchheit and colleagues at Duke has also shown that exosomes in ACS carry out many of the benefits, including pain relief and improved cell function.
View our complete preparation guide covering the 5-day blood draw series and injection schedule.
Regenokine is particularly effective for chronic inflammatory joint conditions
The most common application - excellent results for knee arthritis.
Effective alternative to hip replacement for appropriate candidates.
Facet arthritis, degenerative disc disease, and radicular pain.
Glenohumeral arthritis and chronic shoulder inflammation.
While both use your own blood, they work differently. PRP concentrates platelets and growth factors to stimulate the body’s repair mechanisms. The Regenokine® Program uses multiple complementary elements, including ACS, that work together to promote tissue healing and resolve inflammation.
Many patients notice improvements within the first few days of treatment. The maximum benefit may take several weeks after completing the injection series as cartilage, nerve, and tissue health improve.
Like many regenerative therapies, the Program is often not covered by insurance.
Yes. Although many patients experience extended benefits with the Regenokine® Program, it can be repeated as needed. ACS, the main component of the Program, is derived from the patient’s own blood and does not carry the side effects of other common injections, such as repeated steroids.
Although any injection or procedure can cause side effects, these are uncommon with the Regenokine® Program because most components are derived from the patient's own body. Additionally, the ACS component is prepared under strict sterile conditions in a dedicated laboratory.
Schedule a consultation with Dr. Buchheit to discuss whether Regenokine is right for your condition.
